logo
BioLink 2017 中美医药健康投融资和技术转移大会
Double Tree by Hilton hotel San Francisco Airport

展示生物医药尖端技术,发布生物产业发展形势
解读风险投资者决策依据

BioLink 2017中美医药健康投融资和技术转移大会

主办: 中国医药保健品进出口商会 UBM  
时间: 2017年1月8日 星期日     
地点: Double Tree by Hilton hotel San Francisco Airport
located at 835 Airport Blvd., Burlingame California 94010-9949, USA.

协办 :世易科技  BFC Group 
语言: 英语
联系人: Sammi Wang
Email sammi@echinachem.com


我们很高兴能邀请您来参加由中国医药保健品进出口商会、上海博华国际展览有限公司及世易传媒共同主办的BioLink 2017 中美医药健康投融资和技术转移大会。本届大会将于2017年1月8日在旧金山机场希尔顿酒店举办。您可以联系Sammi Wang sammi@echinachem.com 详询本届会议。以下是本届会议的具体议程。

大会日程


9:00 AM-9:10 AM

开幕致辞          中国 医药保健品进出口商会副会长

欢迎致辞     杨依杭    旧金山总领事馆经济商务参赞

9:10 AM-10:10 AM

在美投资      主持人: 陈大东 BFC Group 总经理

嘉宾

职位

公司

陈鹏辉

合伙人

红杉资本中国基金(医疗投资)

王国玮

合伙人

奥博资本

韩厉玲

董事总经理

阳光保险集团

Jeff Kindler(辉瑞前CEO)

CEO

Centrixon.

10:10 AM-10:30 AM

   

10:30 AM-11:30 AM

在华投资       主持人 吕明华,世易科技 CEO

嘉宾

职位

公司

Dr.Blobel

CEO

赛生制药

赵奕宁

董事总经理

礼来投资资金

杜莹

创始人

再鼎医药

华平

合伙人

软银中国

Guy Villax

CEO

好利安医药

11:30 AM-12:30 PM

企业路演

12:30 PM-1:30 PM

    

1:30 PM-4:00 PM

企业路演

4:00 PM-5:00 PM

跨境交易的最佳结构      主持人: 陈鹏辉,红杉资本中国基金合伙人

嘉宾

职位

公司

傅唯

CEO,合伙人

康桥资本

Michael Rosesal

合伙人

Polsinelli

吉冬梅

董事总经理

金浦投资

5:00 PM-7:00 PM

鸡尾酒会


演讲嘉宾

Ming Xu
Vice President of CCCMHPIE
Dr. Xu is the vice president of China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE). He holds a Ph.D degree of Industry Economy at the School of Management of Fudan University and a post doctoral fellow in business administration at Guanghua School of Management of Peking University. He was active in governmental negotiations including those with APEC, JETC dialogues withUS and UK, and on China-Switzerland FTA. He is also a member of the Market Dynamic Advisory Group of the Global Fund to fight against AIDS,TB and malaria

David Chen
Managing Director, BFC Group
Mr. Chen has over 15 years of management experience in pharmaceutical, diagnostic and medical devices companies in both the US and China. He was a scientist with Bayer Corporation. He was also a business member of a major product launch team with Eli Lilly in the US. He then served as acting CFO at Shanghai Sunway Biotech, a specialty pharmaceutical company focused on oncology, where he was in charge of overall business development and finance. As a co-founder of BFC Group, he has been involved in many cross-border engagements covering business development, private placement, and mergers and acquisitions. His clients include public and private companies, as well as private equity and venture capital funds in the US, Europe and China. Mr. Chen is a published author and inventor. He is also a frequent speaker at healthcare investment conferences. Mr. Chen received his MBA from Kellogg School of Management of the Northwestern University.

Minghua Lu
CEO of eChinaChem, Inc.
Minghua is the CEO and founder of eChinaChem. Before founding eChinaChem, Minghua was the Business Manager at Amazon.com, where he was responsible for critical web metrics in customer acquisition, retention, churn and monetization. Before joining Amazon, he was a management consultant at Booz-Allen & Hamilton. Minghua advised many of the world’s top pharmaceutical, chemical, ,and oil companies on strategic issues. Prior to Booz-Allen, Minghua held managerial and engineering positions in global procurement, marketing and sales, central operation, and product development at companies including ExxonMobil Corporation, Genzyme Corporation, Gentrack division of the BPAmoco Corporation, and China Petrochemical Corporation (SINOPEC). Minghua has an MBA degree from Kellogg School of Management at Northwestern University, an MS degree in Chemical Engineering from Yale University, and a BS degree in Chemical Engineering from China Zhejiang University.

Kevin Chen
Partner Sequoia Capital China
Mr. Chen focuses on investment within the healthcare sector. Prior to joining Sequoia Capital in 2014, Mr. Chen has served as the Managing Director at Everbright Healthcare. At Everbright, Mr. Chen led the fund raising efforts as well as investment in leading healthcare companies in China such as BGI Tech, Amcare, Betta Pharmaceuticals Inc, and Jiwa Pharmaceuticals, Inc. Before Everbright, he served as President of ShangPharma, a leading China CRO company. Kevin was also a Vice President at CITIC Capital, responsible for private equity investment. Before CITIC Capital, Mr. Chen took worked as an executive working in business development and corporate investments at several Fortune 500 multi-national corporations. Mr. Chen also worked as a research scientist at Ligand Pharmaceuticals. Mr. Chen holds a BA in Chemistry from Nanjing University, a Master’s degree in Medicinal Chemistry from Tulane University and an MBA from the Kellogg School of Management of the Northwestern University.

Dr. David Wang
Senior Managing Director, OrbiMed Asia
Dr. Wang was a Managing Director at WI Harper Group, responsible for healthcare investment in China. Previously, he served as Head of Business Development at Siemens Medical Solutions, where he directed corporate strategy and new businesses in molecular diagnostics and diagnostic imaging. He was co-founder and EVP at First Genetic Trust, a personalized medicine company. During his tenure at Bristol-Myers Squibb, he was Chairman of The SNP Consortium Management Committee, the first group of its kind formed by pharmaceutical and technology industries to support the development of personalized medicine. He received his M.D. from Peking University Medical School. He earned his doctorate in Developmental Biology from California Institute of Technology.

Peter Hua
Managing Partner of SB China Capital
Dr. Hua has extensive experience in venture capital investment and operational management in high-tech companies. Since joining SBCVC in 2000, he has been investing in IT, healthcare, clean technology sectors. He led the investment of many well-known companies, including Dian Diagnosics, BGI, Edan, Navinfo, Shenwu, Longxin, GDS and PPTV and served as board members of many portfolios. Prior to joining SBCVC, he was with McKinsey&Company and Siemens (USA). He held US patents, and was a core member of a standard committee in National Electrical Manufacturer Association in USA. Dr. Hua holds B.S. from Shanghai Jiao Tong University, MBA from Kellogg School of Management, Northwestern University, Ph. D. from University of Wisconsin.

Samantha Du
Chairman & Chief Executive Officer, Zai Lab Limited
Dr. Du is a leading figure of China's biotech industry. She is the founder, Chairman and CEO of ZAI Lab, a premier innovative biopharmaceutical company in China. Prior to founding Zai Lab, Dr. Du was head of healthcare investments of Sequoia Capital China Fund and led the investments and served on the boards of Betapharma, BGI Tech, JHL Biotech, and Angel Healthcare, all of which made significant returns to the fund over her two years tenue there. Dr. Du is recognized as a pioneer of the China life sciences industry. As the CEO and founder of Hutchinson MediPharma, she spent ten years building a company with rich pipelines in oncology and autoimmune diseases. Under Dr. Du’s leadership, Hutchison MediPharma became the leader for innovative drug R&D in China, bringing five category 1.1 drugs into clinical trials - including the first drug into CFDA green channel review process, and producing two global phase III ready programs. Dr. Du transformed the company into a global biotech company, and established unique collaboration partnerships with multinational companies including AstraZeneca, J&J, Lilly, Merck Serono and Nestle. Dr. Du was also the co-founder and CSO of Hutchison China Meditech, the first China based innovative drug company listed in overseas stock exchange with a current market cap of over $2 billion.

ZHAO Yining,
Venture Partner, Lilly Asia Ventures
Dr. ZHAO Yining is venture partner at Lilly Asia Ventures and is responsible for Sino-US cross-border pharmaceutical investment projects. He is also the founder of several US biotech companies.Currently, Dr. Zhao is the founder and president of two companies, Veritas Genetics Inc, and Just Biotherapeutics Inc, which respectively specializes in human genetic testing and gene-based drug development and production.Prior to founding Veritas Genetics and Just Biotherapeutics, Dr. Zhao was deeply involved in strategic management, business development, product development and corporate mergers and acquisitions in a number of leading multinational pharmaceutical companies for more than 17 years. He was Executive Director, Global Commercial Operations at Amgen, where he was leading the market entry strategy, business development and commercialization of biosimilars in 20 countries outside US and EU. Prior to joining Amgen, Dr. Zhao was responsible for the Asia Strategy at Pfizer, and oversaw businesses including small molecules, biopharmaceuticals and vaccines. Dr. Zhao received his B.S. in Pharmaceutical Sciences from Fudan University (Shanghai, China), Ph.D. magna cum laude in Analytical Chemistry from Ghent University (Ghent, Belgium), and MBA from Massachusetts Institute of Technology (Cambridge, USA). He has contributed more than 30 peer-reviewed publications and book chapters.

Lily Han, Ph. D., MBA
Head of Healthcare Investment, Sunshine Insurance Group
Sunshine Insurance Group is one of the top 10 Chinese Insurance companies, whose revenue is over 75 billion with managed assets over 580 billion RMB. Dr. Han’s investments cover the whole healthcare ecosystem, including healthcare service industries, healthcare manufacture industries and healthcare finance industries. Dr. Han has rich experiences in health industry on investment and international collaboration. Before joining Sunshine, she worked as General Manager of International & Venture Investment Business Unit of Tasly Pharmaceutical Group, and Deputy General Manager of International Department at Fosun Pharma Group. Before devoting herself in healthcare investment, she also worked in McKinsey, Bank of America and Chinese Academy of Sciences.Dr. Han received both her Ph.D. degree in Molecular Biology and her MBA degree from University of Southern California.

Shirley Xu
Vice President, GP Capital
Ms. Shirley Xu is the Vice President of GP Capital, focusing on cross-boarder healthcare investments. Prior to GP, she served as the VP of Yuan Capital and group leader at Shangpharma. Shirley received her Bachelor's degree in Biology from Peking University, Ph.D. in Genetics from the University of Iowa and MBA course certificates from the Wharton School of the University of Pennsylvania.

Jeff Kindler
CEO of Centrixon.
Jeff Kindler is a healthcare executive, investor and advisor who has held leadership positions at some of the world’s most recognized companies. With more than three decades of experience, Kindler is a leading expert in pharmaceuticals and other health care sectors; corporate legal matters including regulation, litigation, compliance and crisis management; brand and franchise management; and executive leadership. Currently, Kindler serves as CEO of Centrexion Corporation, a privately held biotherapeutics company; Venture Partner at Lux Capital, a leading venture capital firm; and a principal in and advisor to a number of privately held health care firms and sponsors. He is also Global Chair of the GLG Institute, a membership-based learning community for top executives. Kindler serves on the boards of a number of publicly and privately held health care companies as well as several not-for-profit institutions including Tufts University, the National Center on Addiction and Substance Abuse at Columbia University, and the Manhattan Theatre Club. He is also a member of President Obama’s Management Advisory Board.

Guy Villax
CEO of Hovione Pharmaceutical
Guy Villax has been the Chief Executive Officer of Hovione since 1997. Prior to that, he held positions with Price Waterhouse in London and Hovione in the Far East. He has a degree in Accounting and Financial Management from the University College at Buckingham. Guy has been Member of the Board of CEFIC’s European Fine Chemicals Group since 2004, as well as Member of the Board of Rx-360 since 2010 and is currently Vice-Chair.

Michael Rosenthal
Partner at Polsinelli
Michael Rosenthal is a partner at Polsinelli. J.D., University of Michigan Law School B.A., magna cum laude, Washington University in St. Louis With more than two decades of experience representing entrepreneurs and management teams, as well as investors and financial sponsors (including venture capital and private equity funds, hedge funds, angel investors, and strategic investors), Mike helps clients effectively navigate financing transactions in a way that ultimately strengthens the relationship between the parties to the transaction, while still protecting a client’s vital interests.


现场图片


TOP